Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
公司代碼NAUT
公司名稱Nautilus Biotechnology Inc
上市日期Aug 07, 2020
CEOPatel (Sujal)
員工數量155
證券類型Ordinary Share
年結日Aug 07
公司地址2701 Eastlake Ave East
城市SEATTLE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編98102
電話12063332001
網址https://www.nautilus.bio/
公司代碼NAUT
上市日期Aug 07, 2020
CEOPatel (Sujal)